MRC Clinical Trials Unit at UCL
90 High Holborn
Today we welcome the judgement from the Court of Appeal that confirms that NHS England has the ability to fund PrEP. The clinical evidence for PrEP is indisputable. We are confident this will result in NHS England deciding to fund PrEP and a successful discussion with local authorities about administering PrEP. We recognise that there will be short-term cost implications until the patent for the drug ends in 2017, but this should not deter the offer of this game-changing HIV prevention option.
NHS England statement: https://www.england.nhs.uk/2016/11/update-on-prep/